The human regions contributing the most to the NILM molecular signature included genes known for their tumor suppressor effects (PTEN Imp. = [79.6–100]; CDH1 Imp. = [2.6–33.5]), but also pro-tumor related genes (e.g. cellular proliferation markers: KRAS (Imp. = [43.0–70.2]), TOP2A (Imp. = 23.4 in S + uS + H), MK167 (Imp. = 8.1 in uS + H), AKT1 (Imp. = 34.7 in uS + H), MET (Imp. = 7.6 in uS + H); and BCL2 (Imp. = [0.4–21.0]), a gene involved in the inhibition of apoptosis (Table 4, Fig. 4). The gene discussed is BCL2; the disease is neoplasm.